nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—Myocardial ischaemia—Pazopanib—kidney cancer	0.0153	0.0417	CcSEcCtD
Droxidopa—Hyperpyrexia—Paclitaxel—kidney cancer	0.0147	0.0399	CcSEcCtD
Droxidopa—PAH—renal system—kidney cancer	0.0126	0.114	CbGeAlD
Droxidopa—Blood pressure increased—Pazopanib—kidney cancer	0.0123	0.0335	CcSEcCtD
Droxidopa—PAH—kidney—kidney cancer	0.0122	0.11	CbGeAlD
Droxidopa—Myocardial ischaemia—Sorafenib—kidney cancer	0.0105	0.0286	CcSEcCtD
Droxidopa—Myocardial ischaemia—Sunitinib—kidney cancer	0.0101	0.0275	CcSEcCtD
Droxidopa—Cardiac failure congestive—Pazopanib—kidney cancer	0.00987	0.0268	CcSEcCtD
Droxidopa—Blood pressure increased—Sorafenib—kidney cancer	0.00845	0.023	CcSEcCtD
Droxidopa—Blood pressure increased—Sunitinib—kidney cancer	0.00813	0.0221	CcSEcCtD
Droxidopa—DDC—nephron tubule—kidney cancer	0.00792	0.0715	CbGeAlD
Droxidopa—Cardiac failure congestive—Everolimus—kidney cancer	0.00779	0.0212	CcSEcCtD
Droxidopa—Isoprenaline—MAPK1—kidney cancer	0.00764	0.41	CrCbGaD
Droxidopa—DDC—renal system—kidney cancer	0.0072	0.065	CbGeAlD
Droxidopa—Urinary tract infection—Temsirolimus—kidney cancer	0.00711	0.0193	CcSEcCtD
Droxidopa—DDC—kidney—kidney cancer	0.00696	0.0628	CbGeAlD
Droxidopa—Myocardial ischaemia—Paclitaxel—kidney cancer	0.00679	0.0185	CcSEcCtD
Droxidopa—DDC—cortex of kidney—kidney cancer	0.00678	0.0612	CbGeAlD
Droxidopa—Cardiac failure congestive—Sorafenib—kidney cancer	0.00676	0.0184	CcSEcCtD
Droxidopa—Cardiac failure congestive—Sunitinib—kidney cancer	0.00651	0.0177	CcSEcCtD
Droxidopa—ADRA1B—renal system—kidney cancer	0.00568	0.0512	CbGeAlD
Droxidopa—Myocardial ischaemia—Capecitabine—kidney cancer	0.00558	0.0152	CcSEcCtD
Droxidopa—ADRA1B—kidney—kidney cancer	0.00549	0.0495	CbGeAlD
Droxidopa—Blood pressure increased—Paclitaxel—kidney cancer	0.00546	0.0148	CcSEcCtD
Droxidopa—SLC16A10—nephron tubule—kidney cancer	0.00543	0.049	CbGeAlD
Droxidopa—Urinary tract infection—Everolimus—kidney cancer	0.00529	0.0144	CcSEcCtD
Droxidopa—Cardiac failure congestive—Gemcitabine—kidney cancer	0.00522	0.0142	CcSEcCtD
Droxidopa—Hypertension—Temsirolimus—kidney cancer	0.00494	0.0134	CcSEcCtD
Droxidopa—Syncope—Pazopanib—kidney cancer	0.00483	0.0131	CcSEcCtD
Droxidopa—Loss of consciousness—Pazopanib—kidney cancer	0.00474	0.0129	CcSEcCtD
Droxidopa—Hypertension—Pazopanib—kidney cancer	0.00465	0.0126	CcSEcCtD
Droxidopa—SLC16A10—cortex of kidney—kidney cancer	0.00465	0.042	CbGeAlD
Droxidopa—Blood pressure increased—Capecitabine—kidney cancer	0.00448	0.0122	CcSEcCtD
Droxidopa—SLC16A10—gonad—kidney cancer	0.00443	0.04	CbGeAlD
Droxidopa—Urinary tract infection—Sunitinib—kidney cancer	0.00442	0.012	CcSEcCtD
Droxidopa—Cardiac failure congestive—Paclitaxel—kidney cancer	0.00437	0.0119	CcSEcCtD
Droxidopa—Shock—Pazopanib—kidney cancer	0.00433	0.0118	CcSEcCtD
Droxidopa—Arrhythmia—Erlotinib—kidney cancer	0.00421	0.0115	CcSEcCtD
Droxidopa—Syncope—Everolimus—kidney cancer	0.00382	0.0104	CcSEcCtD
Droxidopa—Arrhythmia—Sorafenib—kidney cancer	0.00379	0.0103	CcSEcCtD
Droxidopa—Loss of consciousness—Everolimus—kidney cancer	0.00374	0.0102	CcSEcCtD
Droxidopa—Hypertension—Vinblastine—kidney cancer	0.00369	0.01	CcSEcCtD
Droxidopa—Syncope—Erlotinib—kidney cancer	0.00368	0.01	CcSEcCtD
Droxidopa—Hypertension—Everolimus—kidney cancer	0.00367	0.00999	CcSEcCtD
Droxidopa—Arrhythmia—Sunitinib—kidney cancer	0.00365	0.00992	CcSEcCtD
Droxidopa—ADRB1—cardiac atrium—kidney cancer	0.00361	0.0326	CbGeAlD
Droxidopa—Loss of consciousness—Erlotinib—kidney cancer	0.00361	0.00981	CcSEcCtD
Droxidopa—Shock—Everolimus—kidney cancer	0.00342	0.00929	CcSEcCtD
Droxidopa—ADRA2C—nephron tubule—kidney cancer	0.00334	0.0302	CbGeAlD
Droxidopa—Aminosalicylic Acid—PTGS1—kidney cancer	0.00334	0.179	CrCbGaD
Droxidopa—Syncope—Sorafenib—kidney cancer	0.00331	0.00901	CcSEcCtD
Droxidopa—Shock—Erlotinib—kidney cancer	0.0033	0.00896	CcSEcCtD
Droxidopa—Loss of consciousness—Sorafenib—kidney cancer	0.00325	0.00883	CcSEcCtD
Droxidopa—ADRA1A—renal system—kidney cancer	0.00319	0.0288	CbGeAlD
Droxidopa—Hypertension—Sorafenib—kidney cancer	0.00319	0.00867	CcSEcCtD
Droxidopa—Dizziness—Temsirolimus—kidney cancer	0.00309	0.00839	CcSEcCtD
Droxidopa—SLC6A2—gonad—kidney cancer	0.00308	0.0278	CbGeAlD
Droxidopa—Hypertension—Sunitinib—kidney cancer	0.00307	0.00834	CcSEcCtD
Droxidopa—ADRA2C—renal system—kidney cancer	0.00304	0.0274	CbGeAlD
Droxidopa—Urinary tract infection—Paclitaxel—kidney cancer	0.00297	0.00807	CcSEcCtD
Droxidopa—Shock—Sorafenib—kidney cancer	0.00297	0.00806	CcSEcCtD
Droxidopa—ADRA2C—kidney—kidney cancer	0.00294	0.0265	CbGeAlD
Droxidopa—Arrhythmia—Gemcitabine—kidney cancer	0.00293	0.00796	CcSEcCtD
Droxidopa—Headache—Temsirolimus—kidney cancer	0.00292	0.00795	CcSEcCtD
Droxidopa—Dizziness—Pazopanib—kidney cancer	0.00291	0.00791	CcSEcCtD
Droxidopa—Feeling abnormal—Vinblastine—kidney cancer	0.00287	0.00781	CcSEcCtD
Droxidopa—Feeling abnormal—Everolimus—kidney cancer	0.00286	0.00778	CcSEcCtD
Droxidopa—ADRA2C—cortex of kidney—kidney cancer	0.00286	0.0258	CbGeAlD
Droxidopa—Shock—Sunitinib—kidney cancer	0.00285	0.00776	CcSEcCtD
Droxidopa—Nausea—Temsirolimus—kidney cancer	0.00277	0.00754	CcSEcCtD
Droxidopa—Headache—Pazopanib—kidney cancer	0.00275	0.00749	CcSEcCtD
Droxidopa—ADRA2C—cardiac atrium—kidney cancer	0.00272	0.0246	CbGeAlD
Droxidopa—Mesalazine—PTGS1—kidney cancer	0.00262	0.14	CrCbGaD
Droxidopa—Nausea—Pazopanib—kidney cancer	0.00261	0.0071	CcSEcCtD
Droxidopa—Hypertension—Vincristine—kidney cancer	0.0026	0.00706	CcSEcCtD
Droxidopa—Hypertension—Gemcitabine—kidney cancer	0.00246	0.00669	CcSEcCtD
Droxidopa—Arrhythmia—Paclitaxel—kidney cancer	0.00245	0.00666	CcSEcCtD
Droxidopa—Urinary tract infection—Capecitabine—kidney cancer	0.00244	0.00663	CcSEcCtD
Droxidopa—Cardiac failure congestive—Doxorubicin—kidney cancer	0.00231	0.00629	CcSEcCtD
Droxidopa—Dizziness—Vinblastine—kidney cancer	0.0023	0.00627	CcSEcCtD
Droxidopa—Dizziness—Everolimus—kidney cancer	0.0023	0.00624	CcSEcCtD
Droxidopa—ADRA2A—cortex of kidney—kidney cancer	0.00228	0.0206	CbGeAlD
Droxidopa—Feeling abnormal—Dactinomycin—kidney cancer	0.00226	0.00615	CcSEcCtD
Droxidopa—Dizziness—Erlotinib—kidney cancer	0.00222	0.00602	CcSEcCtD
Droxidopa—Headache—Vinblastine—kidney cancer	0.00218	0.00594	CcSEcCtD
Droxidopa—Headache—Everolimus—kidney cancer	0.00218	0.00591	CcSEcCtD
Droxidopa—ADRA2A—gonad—kidney cancer	0.00217	0.0196	CbGeAlD
Droxidopa—ADRA2A—cardiac atrium—kidney cancer	0.00217	0.0196	CbGeAlD
Droxidopa—Syncope—Paclitaxel—kidney cancer	0.00214	0.00582	CcSEcCtD
Droxidopa—Headache—Erlotinib—kidney cancer	0.0021	0.00571	CcSEcCtD
Droxidopa—Loss of consciousness—Paclitaxel—kidney cancer	0.0021	0.00571	CcSEcCtD
Droxidopa—Nausea—Vinblastine—kidney cancer	0.00207	0.00563	CcSEcCtD
Droxidopa—Nausea—Everolimus—kidney cancer	0.00206	0.00561	CcSEcCtD
Droxidopa—Hypertension—Paclitaxel—kidney cancer	0.00206	0.0056	CcSEcCtD
Droxidopa—Arrhythmia—Capecitabine—kidney cancer	0.00201	0.00547	CcSEcCtD
Droxidopa—Dizziness—Sorafenib—kidney cancer	0.00199	0.00542	CcSEcCtD
Droxidopa—Nausea—Erlotinib—kidney cancer	0.00199	0.00541	CcSEcCtD
Droxidopa—Confusional state—Paclitaxel—kidney cancer	0.00196	0.00534	CcSEcCtD
Droxidopa—Dizziness—Sunitinib—kidney cancer	0.00192	0.00521	CcSEcCtD
Droxidopa—Feeling abnormal—Gemcitabine—kidney cancer	0.00192	0.00521	CcSEcCtD
Droxidopa—Shock—Paclitaxel—kidney cancer	0.00192	0.00521	CcSEcCtD
Droxidopa—Aminosalicylic Acid—PTGS2—kidney cancer	0.00191	0.102	CrCbGaD
Droxidopa—Headache—Sorafenib—kidney cancer	0.00189	0.00513	CcSEcCtD
Droxidopa—Headache—Sunitinib—kidney cancer	0.00182	0.00494	CcSEcCtD
Droxidopa—Nausea—Sorafenib—kidney cancer	0.00179	0.00487	CcSEcCtD
Droxidopa—Syncope—Capecitabine—kidney cancer	0.00176	0.00478	CcSEcCtD
Droxidopa—Nausea—Sunitinib—kidney cancer	0.00172	0.00468	CcSEcCtD
Droxidopa—Loss of consciousness—Capecitabine—kidney cancer	0.00172	0.00468	CcSEcCtD
Droxidopa—Hypertension—Capecitabine—kidney cancer	0.00169	0.0046	CcSEcCtD
Droxidopa—Isoprenaline—CYP1A1—kidney cancer	0.00164	0.0881	CrCbGaD
Droxidopa—Nausea—Dactinomycin—kidney cancer	0.00163	0.00443	CcSEcCtD
Droxidopa—Dizziness—Vincristine—kidney cancer	0.00162	0.00441	CcSEcCtD
Droxidopa—Confusional state—Capecitabine—kidney cancer	0.00161	0.00438	CcSEcCtD
Droxidopa—Feeling abnormal—Paclitaxel—kidney cancer	0.00161	0.00437	CcSEcCtD
Droxidopa—Shock—Capecitabine—kidney cancer	0.00157	0.00428	CcSEcCtD
Droxidopa—Urinary tract infection—Doxorubicin—kidney cancer	0.00157	0.00427	CcSEcCtD
Droxidopa—Headache—Vincristine—kidney cancer	0.00154	0.00418	CcSEcCtD
Droxidopa—Mesalazine—PTGS2—kidney cancer	0.0015	0.0803	CrCbGaD
Droxidopa—Headache—Gemcitabine—kidney cancer	0.00146	0.00396	CcSEcCtD
Droxidopa—Nausea—Vincristine—kidney cancer	0.00146	0.00396	CcSEcCtD
Droxidopa—Nausea—Gemcitabine—kidney cancer	0.00138	0.00376	CcSEcCtD
Droxidopa—Feeling abnormal—Capecitabine—kidney cancer	0.00132	0.00358	CcSEcCtD
Droxidopa—Arrhythmia—Doxorubicin—kidney cancer	0.0013	0.00352	CcSEcCtD
Droxidopa—Dizziness—Paclitaxel—kidney cancer	0.00129	0.0035	CcSEcCtD
Droxidopa—Headache—Paclitaxel—kidney cancer	0.00122	0.00332	CcSEcCtD
Droxidopa—Nausea—Paclitaxel—kidney cancer	0.00116	0.00315	CcSEcCtD
Droxidopa—Syncope—Doxorubicin—kidney cancer	0.00113	0.00308	CcSEcCtD
Droxidopa—Loss of consciousness—Doxorubicin—kidney cancer	0.00111	0.00302	CcSEcCtD
Droxidopa—Hypertension—Doxorubicin—kidney cancer	0.00109	0.00296	CcSEcCtD
Droxidopa—Dizziness—Capecitabine—kidney cancer	0.00106	0.00287	CcSEcCtD
Droxidopa—Confusional state—Doxorubicin—kidney cancer	0.00104	0.00283	CcSEcCtD
Droxidopa—Shock—Doxorubicin—kidney cancer	0.00101	0.00276	CcSEcCtD
Droxidopa—Headache—Capecitabine—kidney cancer	0.001	0.00272	CcSEcCtD
Droxidopa—Nausea—Capecitabine—kidney cancer	0.00095	0.00258	CcSEcCtD
Droxidopa—Feeling abnormal—Doxorubicin—kidney cancer	0.000849	0.00231	CcSEcCtD
Droxidopa—Dizziness—Doxorubicin—kidney cancer	0.000682	0.00185	CcSEcCtD
Droxidopa—Headache—Doxorubicin—kidney cancer	0.000646	0.00176	CcSEcCtD
Droxidopa—Nausea—Doxorubicin—kidney cancer	0.000612	0.00166	CcSEcCtD
Droxidopa—ADRA1D—Signaling Pathways—APC—kidney cancer	4.22e-05	8.38e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—KIT—kidney cancer	4.22e-05	8.38e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—KDR—kidney cancer	4.17e-05	8.29e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—IL2—kidney cancer	4.17e-05	8.29e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—KDR—kidney cancer	4.13e-05	8.22e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—RAF1—kidney cancer	4.13e-05	8.21e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IGF2—kidney cancer	4.12e-05	8.19e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CDKN2B—kidney cancer	4.1e-05	8.15e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—KDR—kidney cancer	4.08e-05	8.11e-05	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—IL2—kidney cancer	4.08e-05	8.11e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—POMC—kidney cancer	4.05e-05	8.05e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—MAPK3—kidney cancer	4.04e-05	8.03e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HIF1A—kidney cancer	4.03e-05	8.02e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TSC2—kidney cancer	4.02e-05	8e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—POMC—kidney cancer	4.01e-05	7.98e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IGF1R—kidney cancer	3.98e-05	7.92e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—PIK3CA—kidney cancer	3.98e-05	7.91e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HIF1A—kidney cancer	3.97e-05	7.9e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—BRAF—kidney cancer	3.96e-05	7.88e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TSC2—kidney cancer	3.96e-05	7.88e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—VEGFA—kidney cancer	3.87e-05	7.7e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—KDR—kidney cancer	3.86e-05	7.67e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—TP53—kidney cancer	3.85e-05	7.65e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—MAPK1—kidney cancer	3.84e-05	7.64e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—KIT—kidney cancer	3.84e-05	7.64e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—APC—kidney cancer	3.84e-05	7.64e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—RAF1—kidney cancer	3.84e-05	7.63e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—APC—kidney cancer	3.81e-05	7.57e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—KIT—kidney cancer	3.81e-05	7.57e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—KDR—kidney cancer	3.8e-05	7.55e-05	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—IL2—kidney cancer	3.79e-05	7.53e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—KIT—kidney cancer	3.76e-05	7.47e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—APC—kidney cancer	3.76e-05	7.47e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—IL2—kidney cancer	3.7e-05	7.36e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—MAPK3—kidney cancer	3.68e-05	7.31e-05	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—PIK3CA—kidney cancer	3.67e-05	7.3e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—MAPK3—kidney cancer	3.66e-05	7.28e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—POMC—kidney cancer	3.66e-05	7.27e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—MAPK3—kidney cancer	3.64e-05	7.25e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—KRAS—kidney cancer	3.63e-05	7.21e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—POMC—kidney cancer	3.62e-05	7.2e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—BRAF—kidney cancer	3.61e-05	7.18e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—MAPK3—kidney cancer	3.6e-05	7.16e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—BRAF—kidney cancer	3.58e-05	7.11e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—POMC—kidney cancer	3.58e-05	7.11e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—MYC—kidney cancer	3.56e-05	7.08e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—KIT—kidney cancer	3.55e-05	7.07e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—APC—kidney cancer	3.55e-05	7.07e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—BRAF—kidney cancer	3.53e-05	7.02e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HIF1A—kidney cancer	3.53e-05	7.01e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TSC2—kidney cancer	3.52e-05	7e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—MAPK1—kidney cancer	3.5e-05	6.96e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—APC—kidney cancer	3.5e-05	6.96e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—KIT—kidney cancer	3.5e-05	6.96e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—MAPK1—kidney cancer	3.48e-05	6.93e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—MAPK1—kidney cancer	3.47e-05	6.9e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—IL2—kidney cancer	3.44e-05	6.84e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—MAPK1—kidney cancer	3.42e-05	6.81e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—MAPK3—kidney cancer	3.4e-05	6.77e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—POMC—kidney cancer	3.38e-05	6.73e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—KDR—kidney cancer	3.37e-05	6.71e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—MAPK3—kidney cancer	3.35e-05	6.66e-05	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—PIK3CA—kidney cancer	3.34e-05	6.65e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—BRAF—kidney cancer	3.34e-05	6.64e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—PIK3CA—kidney cancer	3.33e-05	6.63e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—POMC—kidney cancer	3.33e-05	6.62e-05	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—PIK3CA—kidney cancer	3.31e-05	6.59e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—RAF1—kidney cancer	3.31e-05	6.58e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—KRAS—kidney cancer	3.31e-05	6.57e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—RELA—kidney cancer	3.29e-05	6.55e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—KRAS—kidney cancer	3.29e-05	6.54e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—BRAF—kidney cancer	3.29e-05	6.54e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—POMC—kidney cancer	3.29e-05	6.54e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HIF1A—kidney cancer	3.28e-05	6.52e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—KRAS—kidney cancer	3.28e-05	6.51e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—ERBB2—kidney cancer	3.27e-05	6.51e-05	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—PIK3CA—kidney cancer	3.27e-05	6.51e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TSC2—kidney cancer	3.27e-05	6.5e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—MAPK1—kidney cancer	3.24e-05	6.44e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—KRAS—kidney cancer	3.23e-05	6.43e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MTOR—kidney cancer	3.23e-05	6.42e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PTGS2—kidney cancer	3.23e-05	6.42e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—MAPK1—kidney cancer	3.19e-05	6.34e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—KDR—kidney cancer	3.13e-05	6.23e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—APC—kidney cancer	3.11e-05	6.18e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—KIT—kidney cancer	3.11e-05	6.18e-05	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—PIK3CA—kidney cancer	3.1e-05	6.16e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—KRAS—kidney cancer	3.06e-05	6.08e-05	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—PIK3CA—kidney cancer	3.05e-05	6.06e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—PIK3CA—kidney cancer	3.04e-05	6.04e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CDKN1B—kidney cancer	3.03e-05	6.03e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—PIK3CA—kidney cancer	3.02e-05	6.01e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—RAF1—kidney cancer	3.01e-05	5.99e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—KRAS—kidney cancer	3.01e-05	5.99e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—PIK3CA—kidney cancer	3.01e-05	5.98e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—RELA—kidney cancer	3e-05	5.97e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—RAF1—kidney cancer	2.99e-05	5.94e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—ERBB2—kidney cancer	2.98e-05	5.93e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—MAPK3—kidney cancer	2.98e-05	5.92e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—RELA—kidney cancer	2.97e-05	5.91e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—PIK3CA—kidney cancer	2.97e-05	5.91e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—IL2—kidney cancer	2.97e-05	5.9e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—POMC—kidney cancer	2.96e-05	5.88e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—ERBB2—kidney cancer	2.95e-05	5.88e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—RAF1—kidney cancer	2.95e-05	5.86e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MTOR—kidney cancer	2.94e-05	5.85e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—RELA—kidney cancer	2.94e-05	5.84e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—TP53—kidney cancer	2.92e-05	5.81e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—BRAF—kidney cancer	2.92e-05	5.81e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—ERBB2—kidney cancer	2.92e-05	5.8e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MTOR—kidney cancer	2.92e-05	5.8e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CCND1—kidney cancer	2.89e-05	5.75e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—APC—kidney cancer	2.89e-05	5.74e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—KIT—kidney cancer	2.89e-05	5.74e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—JUN—kidney cancer	2.89e-05	5.74e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MTOR—kidney cancer	2.88e-05	5.72e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CTNNB1—kidney cancer	2.86e-05	5.69e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—MAPK1—kidney cancer	2.83e-05	5.63e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PTEN—kidney cancer	2.81e-05	5.6e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—PIK3CA—kidney cancer	2.81e-05	5.59e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—PTEN—kidney cancer	2.79e-05	5.55e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—RAF1—kidney cancer	2.79e-05	5.55e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—RELA—kidney cancer	2.78e-05	5.52e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—PIK3CA—kidney cancer	2.77e-05	5.5e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	2.77e-05	5.5e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CDKN1B—kidney cancer	2.76e-05	5.49e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—ERBB2—kidney cancer	2.76e-05	5.49e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—POMC—kidney cancer	2.75e-05	5.47e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—RAF1—kidney cancer	2.75e-05	5.46e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CDKN1B—kidney cancer	2.74e-05	5.44e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—RELA—kidney cancer	2.73e-05	5.44e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MTOR—kidney cancer	2.72e-05	5.42e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—ERBB2—kidney cancer	2.72e-05	5.4e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—BRAF—kidney cancer	2.71e-05	5.4e-05	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—PIK3CA—kidney cancer	2.71e-05	5.38e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—IL2—kidney cancer	2.7e-05	5.37e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CDKN1B—kidney cancer	2.7e-05	5.37e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MTOR—kidney cancer	2.68e-05	5.33e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—IL2—kidney cancer	2.68e-05	5.33e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—KRAS—kidney cancer	2.67e-05	5.32e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—IL2—kidney cancer	2.64e-05	5.26e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CCND1—kidney cancer	2.63e-05	5.24e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	2.63e-05	5.23e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—JUN—kidney cancer	2.63e-05	5.23e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PTGS2—kidney cancer	2.62e-05	5.21e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCND1—kidney cancer	2.61e-05	5.19e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CTNNB1—kidney cancer	2.61e-05	5.19e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—JUN—kidney cancer	2.61e-05	5.18e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CTNNB1—kidney cancer	2.59e-05	5.14e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCND1—kidney cancer	2.58e-05	5.13e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—JUN—kidney cancer	2.57e-05	5.11e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CDKN1B—kidney cancer	2.56e-05	5.08e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CTNNB1—kidney cancer	2.55e-05	5.08e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PTEN—kidney cancer	2.54e-05	5.06e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—VEGFA—kidney cancer	2.52e-05	5.01e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PTEN—kidney cancer	2.52e-05	5.01e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CDKN1B—kidney cancer	2.52e-05	5e-05	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	2.51e-05	5e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—IL2—kidney cancer	2.5e-05	4.97e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PTEN—kidney cancer	2.49e-05	4.95e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	2.49e-05	4.94e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—IL2—kidney cancer	2.46e-05	4.9e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	2.46e-05	4.89e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—RAF1—kidney cancer	2.44e-05	4.85e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCND1—kidney cancer	2.44e-05	4.85e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—JUN—kidney cancer	2.43e-05	4.84e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—RELA—kidney cancer	2.43e-05	4.83e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CTNNB1—kidney cancer	2.41e-05	4.8e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	2.41e-05	4.8e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCND1—kidney cancer	2.4e-05	4.77e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—JUN—kidney cancer	2.39e-05	4.76e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MAPK3—kidney cancer	2.38e-05	4.74e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MTOR—kidney cancer	2.38e-05	4.74e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CTNNB1—kidney cancer	2.38e-05	4.73e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PTEN—kidney cancer	2.35e-05	4.68e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MYC—kidney cancer	2.32e-05	4.61e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PTEN—kidney cancer	2.32e-05	4.61e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—VEGFA—kidney cancer	2.3e-05	4.57e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PTEN—kidney cancer	2.29e-05	4.55e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	2.28e-05	4.54e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—VEGFA—kidney cancer	2.28e-05	4.53e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MAPK1—kidney cancer	2.27e-05	4.51e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—RAF1—kidney cancer	2.27e-05	4.51e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—RELA—kidney cancer	2.26e-05	4.49e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—VEGFA—kidney cancer	2.25e-05	4.47e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	2.24e-05	4.46e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	2.23e-05	4.44e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MTOR—kidney cancer	2.21e-05	4.4e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IL2—kidney cancer	2.19e-05	4.35e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MAPK3—kidney cancer	2.17e-05	4.32e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MAPK3—kidney cancer	2.15e-05	4.28e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—KRAS—kidney cancer	2.14e-05	4.26e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCND1—kidney cancer	2.13e-05	4.24e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—JUN—kidney cancer	2.13e-05	4.23e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—VEGFA—kidney cancer	2.13e-05	4.23e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MAPK3—kidney cancer	2.13e-05	4.23e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MYC—kidney cancer	2.11e-05	4.2e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	2.11e-05	4.2e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MYC—kidney cancer	2.09e-05	4.16e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—VEGFA—kidney cancer	2.09e-05	4.16e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	2.08e-05	4.13e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MAPK1—kidney cancer	2.07e-05	4.11e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MYC—kidney cancer	2.07e-05	4.11e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PTEN—kidney cancer	2.06e-05	4.09e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MAPK1—kidney cancer	2.05e-05	4.07e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IL2—kidney cancer	2.03e-05	4.04e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MAPK1—kidney cancer	2.02e-05	4.02e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MAPK3—kidney cancer	2.01e-05	4e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PIK3CA—kidney cancer	1.99e-05	3.95e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCND1—kidney cancer	1.98e-05	3.94e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MAPK3—kidney cancer	1.98e-05	3.94e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—JUN—kidney cancer	1.98e-05	3.93e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—PIK3CA—kidney cancer	1.97e-05	3.92e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	1.96e-05	3.9e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MYC—kidney cancer	1.96e-05	3.89e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—KRAS—kidney cancer	1.95e-05	3.88e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—KRAS—kidney cancer	1.93e-05	3.85e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MYC—kidney cancer	1.93e-05	3.83e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MAPK1—kidney cancer	1.91e-05	3.81e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PTEN—kidney cancer	1.91e-05	3.8e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—KRAS—kidney cancer	1.91e-05	3.8e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TP53—kidney cancer	1.9e-05	3.79e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MAPK1—kidney cancer	1.88e-05	3.75e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	1.86e-05	3.7e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—KRAS—kidney cancer	1.81e-05	3.59e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PIK3CA—kidney cancer	1.79e-05	3.57e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—KRAS—kidney cancer	1.78e-05	3.54e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PIK3CA—kidney cancer	1.78e-05	3.54e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	1.76e-05	3.5e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PIK3CA—kidney cancer	1.75e-05	3.49e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TP53—kidney cancer	1.74e-05	3.45e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	1.73e-05	3.43e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TP53—kidney cancer	1.72e-05	3.42e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MYC—kidney cancer	1.71e-05	3.4e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TP53—kidney cancer	1.7e-05	3.38e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	1.67e-05	3.33e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PIK3CA—kidney cancer	1.66e-05	3.3e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PIK3CA—kidney cancer	1.63e-05	3.25e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	1.63e-05	3.25e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PIK3CA—kidney cancer	1.61e-05	3.21e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TP53—kidney cancer	1.61e-05	3.19e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MYC—kidney cancer	1.59e-05	3.16e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TP53—kidney cancer	1.58e-05	3.14e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—KRAS—kidney cancer	1.58e-05	3.14e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	1.55e-05	3.09e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—KRAS—kidney cancer	1.47e-05	2.92e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	1.45e-05	2.89e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TP53—kidney cancer	1.4e-05	2.79e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	1.35e-05	2.68e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TP53—kidney cancer	1.3e-05	2.59e-05	CbGpPWpGaD
